Document is current

Article History

Received: 1 April 2026

Accepted: 21 May 2026

First Online: 2 June 2026

Declarations

:

: All patients gave written informed consent. The study was approved by the local ethical committee (Ethical board of the Medical Faculty of the Justus-Liebig-University Giessen; 53/23).

: Not applicable.

: F. Axhausen: has no conflict of interest to declare. S. Wolff: received lecturing honoraria from Mylan and Novartis, personal fees from Roche and research support from Novartis. R. Baumgart: received travel reimbursements from Sanofi B. Arneth: has no conflict of interest to declare. A. Mrochen: declares that there are no conflicts of interest in connection with this study, she received honoraria for lectures or consultancy from Alexion, Roche and Novartis and travel expenses to attend meetings from Alexion. H.H. Kraemer: received honoraria for lectures or consultancy work from Argenx, Alexion, J&J, Amgen, UCB, Roche, Novartis, travel expenses to attend meetings from Alexion, Sanofi and Grifols and research support from Roche and Argenx. S. Pfeuffer: received honoraria for lectures or consultation from Alexion, ArgenX, Biogen, Hexal, JUVISE, Merck Healthcare, neuraxpharm, Novartis, Roche and Sanofi, travel reimbursements from Alexion, Biogen, neuraxpharm, Novartis, Roche and Sanofi and research support from Biogen, Merck Healthcare and Novartis.